John Libbey Eurotext

European Journal of Dermatology


Characterization of skin Th17 transcriptional profiles in psoriatic patients under adalimumab biotherapy Volume 27, numéro 6, November-December 2017


  • Figure 1
  • Figure 2
  • Figure 3
  • Figure 4
  • Figure 5


1 CHU de Poitiers, 86021 Poitiers, France
2 Laboratoire Inflammation, Tissus Epithéliaux et Cytokines, LITEC, Université de Poitiers, 86073 Poitiers, France
3 ImageUP, STIM, ERL 7368 Université de Poitiers, 86073 Poitiers, France
* Reprints
  • Mots-clés : cytokine, inflammation, psoriasis, biotherapy, adalimumab
  • DOI : 10.1684/ejd.2017.3127
  • Page(s) : 579-89
  • Année de parution : 2017


In psoriasis, a specific cytokine network has been described to play a central role in the pathophysiology of the disease. Anti-cytokine therapeutic approaches have been largely developed and TNFα constitutes the main target. Adalimumab is a human anti-TNFα monoclonal antibody that has been reported to demonstrate clinical efficacy and safety, resulting in reversal of epidermal hyperplasia and cutaneous inflammation.